Quantitative changes in T-cell populations after left ventricular assist device implantation: Relationship to T-cell apoptosis and soluble CD95

Circulation

Volumn 100, Issue 19 SUPPL., 1999, Pages

  Ankersmit, Hendrik Jan ^a   Edwards, Niloo M ^a   Schuster, Michael ^a   John, Ranjit ^a   Kocher, Alfred ^a   Rose, Eric A ^a   Oz, Mehmet ^a   Itescu, Silviu ^a  

^a Columbia University ^*  (United States)

Author keywords

Apoptosis; Assist devices, left ventricular; Heart failure; Transplantation

Indexed keywords

FAS ANTIGEN; FLUOROCHROME; LIPOCORTIN 5; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT INFECTION; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HELPER CELL; HUMAN; LYMPHOCYTOPENIA; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD95; APOPTOSIS; CROSS-SECTIONAL STUDIES; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; T-LYMPHOCYTE SUBSETS; VENTRICULAR FUNCTION, LEFT;

EID: 0344771177     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301-306.
2. McCarthy PM, Portner PM, Tobler HG, Starnes VA, Ramasamy N, Oyer PE. Clinical experience with the Novacor ventricular assist system. J Thorac Cardiovasc Surg. 1991;102:578-587.
3. Oz MC, Argenziano M, Catanese KA, Gardocki MT, Goldstein DJ, Ashton RC, Gelijn AC, Rose EA, Lewin HR. Bridge experience with long-term implantable left ventricular assist devices: are they an alternative to transplantation? Circulation. 1997;95:1844-1852.
4. Goldstein D, El-Amir NG, Ashton RC, Catanese K, Rose RA, Lewin HR, Oz MC. Fugal infections in left ventricular assist device recipients: incidence, prophylaxis, and treatment. ASAIO J. 1995;41:873-875.
5. McCarthy PM, Schmitt SK, Vargo RL, Gordon S, Keys TF, Hobbs RE. Implantable LVAD infections: implications for permanent use of the device. Ann Thorac Surg. 1996;61:359-365.
6. Argenziano M, Cantanese KA, Moazami N, Gardocki MT, Weinberg AD, Clavenna MW, Rose EA, Scully BE, Lewin HR, Oz MC. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant. 1997;16:822-831.
7. Fischer SA, Trenholme GM, Costanzo MR, Piccione W. Infectious complications in left ventricular assist device recipients. Clin Infect Dis. 1997;24:18-23.
8. Weyand M, Hermann M, Kondruweit M, Deng MC, Schmid C, Peters S, Scheld HM. Clinical impact of infections in left ventricular assist device recipients: the importance of site and organism. Transplant Proc. 1997; 29:3327-3329.
9. McBride LR, Ruzevich SA, Pennington DG, Kennedy DJ, Kanter KR, Miller LW, Swarz MT, Termuhlen DF. Infectious complications associated with ventricular assist device support. ASAIO Trans. 1987;33: 201-202.
10. Massad MG, Cook DJ, Schmitt SK, Smedira NG, McCarthy JF, Vargo RL, McCarthy PM. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64:1120-1125.
11. Itescu S, Tung T, Burke E, Weinberg A, Moazami N, Artrip JH, Suciu Foca N, Rose EA, Oz M, Suciu-Foca N, Michler R. Preformed IgG antibodies against major histocompatibility class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation. 1998;98:786-793.
12. Moazami N, Itescu S, Williams M, Argenziano M, Weinberg A, Oz M. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant. 1998;17:876-880.
13. Alcocer-Verela J, Alarcon-Segovia D. Decreased production of and response to IL-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982;69:1388-1392.
14. Huang YP, Miescher PA, Zubler RH. The interleukin 2 secretion defect in vitro in patients with systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol. 1986;137:3515-3520.
15. Klinman DM, Shirai A, Ishigatsubo Y, Conover J, Steinberg AD. Quantitation of IgM-and IgG-secreting B cells in the peripheral blood of patients with SLE. Arthritis Rheum. 1991;34:11-15.
16. Bernard C, Exquis B, Reber A, deMoerloose P. Determination of anticardiolipin and other antibodies in HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1990;3:536-539.
17. Sollinger AM, Hess EV. Induction of autoantibodies by HIV infection and their significance. Rheum Dis Clin North Am. 1991;17:157-176.
18. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fa/APO-1)-mediated T cell apoptosis. J Exp Med. 1996;184:765-778.
19. Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Nat Acad Sci U S A. 1996;93:1624-1629.
20. Bach JF, Koutouzov S. Immunology: new clues to systemic lupus. Lancet. 1997;350(suppl 3):SIII11. Review.
21. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today. 1991;12:102-105.
22. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus infected asymptomatic individuals. J Exp Med. 1992;1:175:331-340.
23. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, Elkon KB. The APO-1/Fas protein in human systemic lupus erythematosus. J Clin Invest. 1994;93:1029-1034.
24. Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M. High levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus. 1998;7:113-118.
25. Cameron PU, Pope M, Gezelter S, Steinman RM. Infection and apoptotic cell death of CD4+ T cells during an immune response to HIV-1-pulsed dendritic cells. AIDS Res Hum Retroviruses. 1994;10:61-71.
26. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A. Apoptosis occurs primarily in bystander cells and not in productively infected cells of HIV and SIV-infected lymph nodes. Nat Med. 1995;1:129-134.
27. Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, Stern D, Rose EA, Schmidt AM. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg. 1996;112:1090-1097.
28. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO-1 contains a sequence motif related to the death domain. J Biol Chem. 1995;270:7795-7798.
29. Cheng J, Zhou T, Liu C. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759-1762.
30. Tokano Y, Miyake S, Kayagaki K. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. J Clin Immunol. 1996;16: 261-265.
31. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 1997;40:1126-1129.
32. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med. 1995; 181:2029-2036.
33. Orlikowski T, Wang ZQ, Dudhane A, Horowitz H, Riethmuller G, Hoffmann MK. Cytotoxic monocytes in the blood of HIV type 1-infected subjects destroy targeted T cells in a CD95-dependent fashion. AIDS Res Hum Retroviruses. 1997;13:953-960.
34. Spanier TB, Rose S, Schmidt AM, Itescu S. Interactions between dendritic cells and T cells on the surface of left ventricular assist devices leads to a TH2 pattern of cytokine production and B cell hyperreactivity in vivo. Circulation. 1996;94(suppl I):I-293.
35. Spanier TB, Oz MC, Rose EA, Schmidt AM. Activation of NF-KB is central to the proinflammatory/procoagulant response in textured surface left ventricular assist device recipients and may be influenced by anti-inflammatory intervention with aspirin. J Heart Lung Transplant. 1997;17:80.
36. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81:505-512.
37. Boldin MP, Goncharov TM, Golstev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell. 1996;85:803-815.
38. Muzio M, Chinnaiyan AM, Kischel FC, O'Rourke K, Shevchenko A, Ni J, Scaffichi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VA. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 1996;85:817-827.
39. Hu S, Vicenz C, Ni J, Genz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD95-induced apoptosis. J Biol Chem. 1997;272:17255-17257.
40. Irmler M, Thorne M, Hahne M, Schneider P, Hofman K, Steiner V, Bodmer JL, Schroten M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195.
41. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2 regulated Fas-mediated T cell apoptosis. Immunity. 1998;8:615-623.
42. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol. 1998;160:3194-3206.
43. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubl A, Echeverri F, Martin SJ, Farce WR, Lynch DH, Ware CF. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature. 1995;373:441-444.
44. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature. 1995;373: 438-441.
45. Ju ST, Panka DJ, Cui H, Ettinger R, E-Khatib M, Sherr DH, Stanger BZ, Marschak-Rothstein A. Fas(CD95)/Fas ligand interactions required for programmed cell death after T-cell activation. Nature. 1995;373: 444-448.
46. Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas: differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK 506. Int Immunol. 1996;8:1017-1026.